



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: EIS-SCHWARTZ21A

In re Application of:)	Confirmation No.: 3865
Michal EISENBACH-SCHWARTZ et al))	
)	Art Unit:
)	
Appln. No.: 10/807,414)	Examiner:
)	
Filed: March 24, 2004)	Washington, D.C.
)	
For: POLY-GLU, TYR FOR)	August 3, 2004
NEUROPROTECTIVE THERAPY)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT [IDS]

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[X] B. before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents,

publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.


3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. Other information being provided for the examiner's consideration follows:


5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By: 
Roger L. Browdy
Reg. No. 25,618

RLB:ses
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\B\BENA\Eis-Schwartz21A\pto\IDS.doc



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	10/807,414
Filing Date	March 24, 2004
First Named Inventor	Michal Eisenbach-Schwartz
Group Art Unit	1647
Examiner Name	
Attorney Docket Number	EIS-SCHWARTZ21A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AN	WO 03/002140 A1	01-09-2003	Yeda Res and Dev Co Ltd		
	A0	WO 03/047500 A2	06-12-2003	Yeda Res and Dev Co Ltd		

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/807,414
		Filing Date	March 24, 2004
		First Named Inventor	Michal Eisenbach-Schwartz
		Group Art Unit	1647
		Examiner Name	
		Attorney Docket Number	EIS-SCHWARTZ21A
Sheet	2	of	2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AP	ANGELOV et al, "Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis", <u>Proc Natl Acad Sci USA</u> 100(8):4790-4795 (2003)	
	AQ	DEBRÉ et al, "Genetic control of specific immune suppression. II. <i>H-2</i> -linked dominant genetic control of immune suppression by the random copolymer L-glutamic acid ⁵⁰ -L-tyrosine ⁵⁰ (GT)", <u>J Exp Med</u> 142(6):1447-1454 (1975)	
	AR	HIRSCHBERG et al, "Accumulation of passively transferred primed T cells independently of their antigen specificity following central nervous system trauma", <u>J Neuroimmunol</u> 89(1-2):88-96 (1998)	
	AS	KIPNIS et al, "T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.", <u>Proc Natl Acad Sci USA</u> 97(13):7446-7451 (2000)	
	AT	KIPNIS et al, "Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity", <u>J Neuroimmunol</u> 130(1-2):78-85 (2002)	
	AU	KIPNIS et al, "Neuroprotective autoimmunity: naturally occurring CD4 ⁺ CD25 ⁺ regulatory T cells suppress the ability to withstand injury to the central nervous system", <u>Proc Natl Acad Sci USA</u> 99(24):15620-15625 (2002)	
	AV	MOALEM et al, "Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy", <u>Nat Med</u> 5(1):49-55 (1999)	
	AW	SCHWARTZ et al, "Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries", <u>Trends Mol Med</u> 7(6):252-258 (2001)	
	AX	SEO et al, "Activation of murine epidermal V γ 5/V δ 1-TCR ⁺ T cell lines by Glu-Tyr polypeptides", <u>J Invest Dermatol</u> 116(6):880-885 (2001)	
	AY	YOLES et al, "Protective autoimmunity is a physiological response to CNS trauma", <u>J Neurosci</u> 21(11):3740-3748 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.